Healthcare & Life Sciences
Weekly Roundup
Weekly Brief — Healthcare & Life Sciences
India Healthcare & Pharma Intelligence: 2026 Expansion Milestone
This report covers the Indian healthcare and pharmaceutical landscape from March 09 to March 16, 2026. Brought to you by policyindex.ai. This intelligence contains critical updates on regulatory shifts in allied health professions, the rejection of PLI extensions for APIs, and new infrastructure milestones in the MedTech and biopharma sectors.
Key Statistics
| ₹600 Cr - ₹700 Cr | $4 Billion | ₹4,728.42 Cr |
|---|---|---|
| Investment for new MNC pharma facility in Kathua, J&K | India's Medical Device Exports in FY25 | Total 3-year sales at Janaushadhi Kendras |
Weekly Executive Summary
- Regulatory Rigor: The MoHFW notified the NCAHP (Amendment) Rules, 2026, enforcing strict 2-year term limits for Commission members and mandating standardized financial disclosures.
- Industrial Strategy: The Department of Pharmaceuticals (DoP) formally rejected the industry's request for a PLI extension for Bulk Drugs to maintain performance accountability, while pivoting focus to the ₹10,000 Cr Biopharma SHAKTI scheme.
- Market Targets: The Department of Commerce launched the "30@2030" initiative, …
Download Full Intelligence Brief (PDF)
Sign in to your PolicyIndex account to download the complete executive-ready PDF report including all policy exhibits, data tables, and strategic recommendations.
Log In to Download PDF Brief →